Company intelligence / Profile preview
Thunder Biotech
- Ownership
- Private
- Development stage
- Other
Overview
Thunder Biotech is developing genetically engineered CAR macrophages (MOTO-CAR™) that help cancer patients' immune cells recognize and attack solid tumors. Their technology re-educates Tumor Associated Macrophages and restores their ability to recognize and eliminate tumor cells. The company has at least two drug candidates in preclinical stages.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Genetically engineered macrophagesCAR macrophagesSynthetic peptides
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Thunder Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thunder Biotech.